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human, tissue-specific differences in the function of
MYO7A might result in specific mutations having dif-
ferent effects in the eye but similar effects in the inner
ear. It seems likely, however, given (a) the wide range of
MYO7A mutations identified for both nonsyndromic
deafness and USH and (b) the results reported in the
present study, that genetic background effects have some
role to play in determining the development and severity
of nonsyndromic and syndromic hearing loss.
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Haplotype Analysis in Icelandic Families Defines a
Minimal Interval for the Macular Corneal Dystrophy
Type I Gene
To the Editor:
Macular corneal dystrophy (MCD [MIM 217800]) is a
rare autosomal recessive disorder that is clinically char-
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acterized by progressive corneal stromal clouding and
central corneal thinning in both eyes (Ehlers and Thor-
kild 1978; Klintworth 1980, 1994; Donnenfeld 1986).
Depending on the population, MCD comprises 10%–
75% of the corneal dystrophies requiring penetrating
keratoplasty (Jonasson et al. 1989, 1996; Santo et al.
1995). In Iceland, for example, MCD is the most fre-
quent condition necessitating penetrating keratoplasty,
and it accounts for almost one-third of all corneal grafts
performed there (Jonasson et al. 1996). At least two
varieties of MCD have been identified, on the basis of
whether antigenic keratan sulfate (aKS) is identified in
the corneal stroma and serum by an enzyme-linked im-
munosorbent assay (ELISA) using monoclonal antibod-
ies (Yang et al. 1988). In MCD type I, neither the cornea
nor the serum contains appreciable levels of aKS. In
contrast, MCD type II patients have detectable aKS in
the cornea and serum (Yang et al. 1988). Recently, an
additional immunophenotype of MCD (type IA) has
been described in families from Saudi Arabia (Klint-
worth et al. 1997). In these individuals, aKS immuno-
reactivity is not detected in both serum and corneal
stroma, but the accumulations within the keratocytes
react with the anti–keratan sulfate antibody (Klintworth
et al. 1997).
In a previous linkage study, we localized the MCD
type I gene to an interval of ∼7 cM on the long arm of
chromosome 16 (16q22), flanked by the markers
D16S512 and D16S518 (Vance et al. 1996). Analysis of
several MCD type II families by means of the identical
microsatellite markers used for MCD type I provided a
maximum LOD score of 2.5. Given the prior finding
that MCD type I is linked to these identical markers,
this result suggests that the MCD type II gene may be
linked to the same small region as is MCD type I (Vance
et al. 1996). Moreover, elsewhere we have reported an
unusual family in which both MCD type I individuals
and MCD type II individuals coexist in a single sibship
and share one identical disease haplotype, again sug-
gesting the possible allelic manifestation of MCD types
I and II (Liu et al. 1998). Here we report haplotype
analysis of 10 Icelandic families, narrowing the interval
for the MCD type I gene to a very small region, !1 cM.
In addition, several MCD type II individuals were found
to share one of the MCD disease haplotypes, supporting
our previous observations that these different MCD im-
munophenotypes may be allelic (Vance et al. 1996; Liu
et al. 1998).
Twelve MCD individuals from 10 Icelandic families
were used for haplotype analysis. The diagnosis of MCD
was based on a combination of the clinical presentations
and the typical histopathologic features of the dystrophy
in corneal tissue obtained after penetrating keratoplasty
(Klintworth 1994). To determine the specific immuno-
phenotypes, serum levels of aKS were determined by
means of a well-established ELISA and an anti–keratan
sulfate monoclonal antibody (5-D-4) (ICN Biomedical)
directed against a highly sulfated epitope present on ker-
atan sulfate chains (Thonar et al. 1985, 1986). The im-
munohistochemical evaluation of the excised corneal tis-
sue used the same antibody on pathologic corneal tissue
(Yang et al. 1988).
Constitutional DNA from each individual was ex-
tracted as described elsewhere (Pericak-Vance et al.
1988) and was genotyped with 16 polymorphic makers
in the MCD region. Microsatellite repeats were amplified
by PCR as described elsewhere (Ben Othmane et al.
1993). PCR products were electrophoresed on 6.5%
polyacrylamide gels. Gels were then stained with
SyberGreen (Molecular Probes) and were detected by a
FluorImager SI (Molecular Dynamics) or Hitachi FMBio
II (Hitachi Software; Engineering America). To ensure
accuracy of allele analysis, PCR products from all af-
fected individuals were analyzed side-by-side on the
same gel, and DNA from control individuals (CEPH
952645 and CEPH 952646) was amplified and analyzed
at the same time, for comparison of different gels. Hap-
lotype analysis was performed as described elsewhere
(Ben Othmane et al. 1993). Allele frequencies were de-
termined by use of DNA extracted from the blood of
50 unrelated Icelandic controls. All marker data were
entered into a database and were managed by means of
the PEDIGENE system (Hayes et al. 1995).
The initial framework marker order of cen-
D16S3033-D16S512-D16S3018-D15S515-D16S3097-
D16S3101-D16S3125-D16S518-tel was based on the
Ge´ne´thon genetic map (Dib et al. 1996) and the White-
head physical map. However, for fine mapping of the
order of microsatellite markers used in this study, we
constructed a YAC contig to span the MCD region (fig.
1). The CEPH YAC megabase library on 230 96-well
plates (Cohen et al. 1993), available from the Duke Cen-
ter of Human Genetics, was the source for contig for-
mation. DNAs from these plates were pooled on the
basis a two-dimensional PCR screening strategy (Ame-
miya et al. 1992; Ben Othmane et al. 1995). Microsat-
ellite markers were then screened by PCR through the
first dimension, which comprised 23 pools of 10 plates
each. The corresponding second-dimension pools (com-
prising 20 pools of rows or columns of 23 plates each)
were subsequently screened to identify the YACs positive
for the specific marker. PCR-positive clones were cul-
tured, and YAC DNA was extracted from these cultures.
The presence of markers then was verified by reampli-
fication of the sequences from the extracted DNAs. The
PCR reaction was performed by means of a Hybaid
OmniGene thermocycler, as described elsewhere
(Ben Othmane et al. 1993). The markers D16S2624,
D16S738, afm112xh2, D16S3115, D16S3118,
D16S3083, JSB16A, and D16S266 were ordered by
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Figure 1 YAC contig of MCD region. Markers were ordered on the basis of combined physical mapping data; square brackets denote
that marker order is unknown.
physical mapping on the constructed YAC contig (fig.
1). However, at this time, D16S3115 and D16S3118 are
not connected by any YAC, leaving a gap between these
two markers.
Except for one previously unpublished dinucleotide-
repeat marker (JSB16A [forward primer, 5′-CCA TAG
AAG ACT AGT AGG CA-3′; reverse primer 5′-TCA
ATA GCT TGG AGG TTA G-3′; product size 204–230
bp]), the primer sequences for all markers were obtained
through the Genome Database interactive network.
JSB16A was isolated, by means of an indirect sequencing
method, from a P1-derived artificial chromosome (PAC)
clone 134d23, which was obtained by screening the PAC
library filters (Genome Systems) by use of D16S266. The
indirect sequencing method is a modification of that pre-
viously reported by Browne and Litt (1992) and Loeb
et al. (1994) and consisted of two sequencing steps. In
short, the first sequencing was performed on purified
PAC DNA, by use of CA-repeat primers (CA10A/G/T-A,
CA10A/G/T-C, CA10A/G/T-G, CA10A/G/T-T, AC10C/G/T-
A, AC10C/G/T-C, AC10C/G/T-G, and AC10C/G/T-T). A
reverse primer then was designed from the successful first
sequences and was used to sequence back to span the
CA-repeat region. A forward primer then was obtained
from the second sequencing.
The MCD haplotypes of the 12 Icelandic individuals
(8 MCD type I and 4 MCD type II) from 10 families
are shown in figure 2. Among the 24 MCD-bearing chro-
mosomes, five different haplotypes (haplotypes 1–5)
were found that spanned the MCD type I region. Three
of these were found in MCD type I patients, whereas
two were found exclusively in MCD type II families.
Given the known homogeneity of the Icelandic popu-
lation (Jonasson et al. 1996; Vance et al. 1996), the
multiple haplotypes for each type were unexpected.
Haplotype 1 was the major haplotype, presenting, in its
complete form, in four families, three of which contained
MCD type I patients and one of which was a MCD type
II family. Haplotype 2 was present in two MCD type I
patients from the same family. Haplotypes 3 and 3a,
which differ only in having one marker outside the MCD
region, were detected in three MCD type II patients from
three different families. Haplotypes 4 (MCD type I) and
5 (MCD type II) differed significantly from the existing
haplotypes and were each found in one family. The dif-
ferent MCD type I haplotypes may represent different
mutation events in the population, which seems unlikely,
or some or all of the haplotypes may reflect a single
mutation, with the ancestral recombinations rendering
the shared region too small to be seen by the current
resolution of polymorphic markers. Further genotyping
in the minimal candidate region should clarify this point.
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Figure 2 Haplotypes of 12 MCD individuals from 10 Icelandic families. From top to bottom, markers are listed from centromere to
telomere. The major ancestral founder haplotypes and the identifiable cosegregating traces are shaded or boxed. On the basis of ancestral
recombinations, the MCD type I locus has been inferred to be flanked by markers D16S3115 and D16S3083.
Among the haplotypes derived from ancestral hap-
lotype 1, the disease chromosomes could be distin-
guished from the putative haplotype 1 by one or two
recombination events. Interestingly, three individuals
with MCD type II (patients 4, 6, and 8) were found to
share the same haplotype, haplotype 1, as was seen in
MCD type I patients. In earlier studies, we had suggested
that MCD types I and II may be linked to the same small
region of chromosome 16 and thus may be allelic (Vance
et al. 1996; Liu et al. 1998). The finding in the current
study further supports these previous observations.
However, although suggestive, they do not prove that
these two immunophenotypes are allelic. Since this over-
lap in haplotypes could be secondary to chance, we also
haplotyped 21 Icelandic controls, for these same mark-
ers. None of the five MCD haplotypes was found in these
control individuals. Interestingly, allelic heterogeneity
for the 5q31-linked corneal dystrophies has been re-
ported elsewhere (Munier et al. 1997). It has been found
that mutations originating from a single gene for kerato-
epithelin (big-h3) (Skonier et al. 1992) are responsible
for four corneal dystrophies, including granular dystro-
phy (Groenouw type I), Reis-Bucklers, lattice type I, and
Avellino (Munier et al. 1997). Finally, it is possible, al-
though less likely, that MCD types I and II share the
same two mutations and that the currently noted dif-
ferences are not due to different alleles but are secondary
to either epistasis or modifying genes. Final knowledge
of the actual relationship between MCD types I and II
awaits identification of the MCD types I and II gene(s).
If one uses only MCD type I patients, then haplotype
1f shows an ancestral recombination with D16S3115
and thus is the centromeric boundary for the MCD type
I locus. Moreover, haplotype 1d shows a recombination
with D16S3083, on the telomeric side. The MCD type
I locus thus can be refined to the DNA region between
markers D16S3115 and D16S3083, which corresponds
to an approximate genetic distance of !1 cM (Dib et al.
1996). Interestingly, if MCD types I and II are indeed
allelic, then haplotype 1e from an individual with MCD
type II would localize D16S3118 as the telomeric marker
for the MCD gene.
One rare allele identified the haplotype as well. The
242-bp allele with marker D16S515, which existed in
17 (70.8%) of the 24 disease haplotypes (fig. 2), was
found in only 9 of 100 Icelandic normal controls’ chro-
mosomes. The 123-bp allele with D16S3118 and the 96-
bp allele with D16S266 existed in 23 (95.6%) of the 24
disease haplotypes (fig. 2). However, these two alleles
are common alleles in the normal Icelandic population,
with frequencies of .64 and .51 respectively.
Unfortunately, the YAC contig still has a gap between
D16S3115 and D16S3118 (fig. 1). Efforts currently are
being conducted to cross the minimal candidate region
for MCD (D16S3115-D16S3083) with a PAC/BAC
(bacterial artificial chromosome) contig.
In summary, this study indicates that the MCD type
I gene is localized between markers D16S3115 and
D16S3083, which corresponds to a genetic distance of
!1 cM. This represents a significant refinement of the
MCD candidate interval and should facilitate the ulti-
mate cloning of the MCD gene. In addition, it suggests
either that multiple mutations may have led to MCD
type I in Iceland or that MCD is due to an extremely
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old mutation, with multiple recombinants having oc-
curred since its inception.
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Table 1
World Distribution of MTHFR T677
POPULATION
NO. OF
CHROMOSOMES
MUTANT ALLELE
No.
Frequency 
Standard Error
European:
Italian (Calabria) 96 43 .448  .051
Spanisha 66 36 .545  .061
Sub-Saharan African:
Dendi 24 0 0
Bariba 26 2 .077  .052
Berba 32 3 .094  .051
Fon 96 8 .083  .028
Totalb 178 13 .073  .019
Asian:
Tharua 108 21 .194  .038
Chinesea 24 9 .375  .099
Indonesian 98 2 .020  .014
Amerindian:
Cayapaa 114 49 .430  .046
Mixed:
Ethiopian:
Amhara 54 4 .074  .033
Oromo 54 3 .055  .031
Totalb 108 7 .065  .024
African Ecuadoran:
Vichea 82 13 .183  .043
a Testable population, except for Calabrians (Italy), in Hardy-Wein-
berg equilibrium.
b Populations were pooled when compatibility was verified by a x2
test of heterogeneity.
J, Pericak-Vance MA, et al (1996) Linkage of a gene for
macular corneal dystrophy to chromosome 16. Am J Hum
Genet 58:757–762
Yang CJ, SundarRaj N, Thonar EJ, Klintworth GK (1988)
Immunohistochemical evidence of heterogeneity in macular
corneal dystrophy. Am J Ophthalmol 106:65–71
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Heterogeneity in World Distribution of the
Thermolabile C677T Mutation in 5,10-
Methylenetetrahydrofolate Reductase
To the Editor:
Hyperhomocysteinemia now is recognized as an inde-
pendent risk factor for vascular disease (Clarke et al.
1991) and defects of the neural tube (Mills et al. 1995).
Genetic factors associated with hyperhomocysteinemia
are mutations in genes coding for enzymes involved in
the methionine-metabolism pathway, such as 5,10-
methylenetetrahydrofolate reductase (MTHFR) and cys-
tathionine b-synthase. Related environmental factors in-
clude low dietary intake or increased necessity of folate
or vitamins B6 and B12 (Fenton and Rosenberg 1995).
Recently, a common thermolabile MTHFR variant,
causing mild hyperhomocysteinemia in 30% of homo-
zygotes, was detected. The C677T single-nucleotide sub-
stitution was found to cause an amino acid change, from
alanine to valine (Frosst et al. 1995). The T677 allele is
distributed widely among populations showing a high
heterogeneity. The purpose of this study was to inves-
tigate the prevalence of the C677T MTHFR mutation
among the major ethnic groups. The high prevalence of
T677 homozygotes in preselected populations would re-
sult in the need for a higher dietary intake of folate, to
prevent in utero neural-tube defects and long-term vas-
cular damage (Molloy et al. 1997).
We studied a total of 437 unrelated, apparently
healthy subjects from the major ethnic groups, catego-
rized as follows: 81 Europeans (33 Spanish and 48 Ital-
ians); 89 sub-Saharan Africans (48 Fon, 13 Bariba, 16
Berba, and 12 Dendi); 115 Asians (49 Indonesians
[Java], 12 Chinese [Peking area], and 54 Tharus); 57
Amerindians (Cayapa population [Ecuador]); and some
mixed populations, namely, 54 Ethiopians (27 Amhara
and 27 Oromo) and 41 African Ecuadorans (Viche area).
All the subjects gave their informed consent for the study.
For information on the origins of the populations and
their geographical distribution, see the article by Pepe
et al. (1997) and the references cited therein. Genomic
DNA was extracted from peripheral blood–cell lym-
phocytes, was amplified by PCR, and was digested with
HinfI restriction enzyme. The bands were visualized by
ethidium-bromide staining, as described elsewhere (Ab-
bate et al. 1998). The mutation creates a new HinfI site,
which is absent in the wild-type allele. Pooled frequen-
cies were obtained as mean frequencies weighted for the
sample size, after the compatibility of the allele fre-
quencies was verified by the x2 test of heterogeneity.
Results are reported in table 1.
Our data show a marked heterogeneity in the prev-
alence of the T677 MTHFR allele among the major eth-
nic groups surveyed and, in some cases, evenwithin these
groups. The frequency among Europeans ranged from
.448 in Italian subjects to .545 in Spanish subjects,
whereas the prevalence among Asians and Africans was
within the ranges .041–.375 and 0–.094, respectively.
For the Amhara and the Oromo, the frequency of the
T677 allele was intermediate between that for the Eur-
opeans (∼.5) and the sub-Saharan Africans (!.1); this
also has been confirmed in previous studies on genetic
admixture in these populations (Scacchi et al. 1994; O.R.
